| Regimen . | Patients, n . | RR, % . | MST (95%CI), mo . | HR (95% CI) . | p value . |
|---|---|---|---|---|---|
| Platinum doublets | 110 | 21.6 | 22.4 (16.1–28.4) | 1.00 | |
| Other multidrug chemotherapy | 26 | 13.6 | 25.7 (11.5–37.0) | 1.116 (0.667–1.789) | .665 |
| Monotherapy | 55 | 19.6 | 21.4 (13.5–31.8) | 1.193 (0.794–1.766) | .389 |
| All regimens | 191 | 20.0 | 22.4 (17.5–26.7) |
| Regimen . | Patients, n . | RR, % . | MST (95%CI), mo . | HR (95% CI) . | p value . |
|---|---|---|---|---|---|
| Platinum doublets | 110 | 21.6 | 22.4 (16.1–28.4) | 1.00 | |
| Other multidrug chemotherapy | 26 | 13.6 | 25.7 (11.5–37.0) | 1.116 (0.667–1.789) | .665 |
| Monotherapy | 55 | 19.6 | 21.4 (13.5–31.8) | 1.193 (0.794–1.766) | .389 |
| All regimens | 191 | 20.0 | 22.4 (17.5–26.7) |
Abbreviations: CI, confidential interval; HR, hazard ratio; MST, median survival time; RR, response rate.
| Regimen . | Patients, n . | RR, % . | MST (95%CI), mo . | HR (95% CI) . | p value . |
|---|---|---|---|---|---|
| Platinum doublets | 110 | 21.6 | 22.4 (16.1–28.4) | 1.00 | |
| Other multidrug chemotherapy | 26 | 13.6 | 25.7 (11.5–37.0) | 1.116 (0.667–1.789) | .665 |
| Monotherapy | 55 | 19.6 | 21.4 (13.5–31.8) | 1.193 (0.794–1.766) | .389 |
| All regimens | 191 | 20.0 | 22.4 (17.5–26.7) |
| Regimen . | Patients, n . | RR, % . | MST (95%CI), mo . | HR (95% CI) . | p value . |
|---|---|---|---|---|---|
| Platinum doublets | 110 | 21.6 | 22.4 (16.1–28.4) | 1.00 | |
| Other multidrug chemotherapy | 26 | 13.6 | 25.7 (11.5–37.0) | 1.116 (0.667–1.789) | .665 |
| Monotherapy | 55 | 19.6 | 21.4 (13.5–31.8) | 1.193 (0.794–1.766) | .389 |
| All regimens | 191 | 20.0 | 22.4 (17.5–26.7) |
Abbreviations: CI, confidential interval; HR, hazard ratio; MST, median survival time; RR, response rate.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
